2019
Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.
Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B, Lin P, Mukherjee B. Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urology Practice 2019, 6: 234-242. PMID: 31276025, PMCID: PMC6605774, DOI: 10.1097/upj.0000000000000020.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen signaling inhibitorsAdvanced prostate cancerFirst-line treatmentProstate cancerSystemic treatment of advanced prostate cancerDatabase of commercially insured patientsTreatment of advanced prostate cancerCastration-resistant prostate cancerSignaling inhibitorsPre-existing heart failureImproved overall survivalTreatment of menCommercially insured patientsSipuleucel-TRadium-223Overall survivalSystemic treatmentTreatment patternsNovel therapiesMedical oncologistsHeart failureMultivariate analysisProvider specialtyDocetaxel
2018
Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer.
Caram M, Wang S, Cheng P, Griggs J, Lin P, Mukherjee B. Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer. Journal Of Clinical Oncology 2018, 36: e17019-e17019. DOI: 10.1200/jco.2018.36.15_suppl.e17019.Peer-Reviewed Original ResearchTemporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy